Trade URGN anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
UroGen Pharma Ltd. (URGN) is trading at US$44.34, up 0.56% today as of Sep 8, 09:56 EDT. The company has a market capitalisation of US$2.29B. Over the past 52 weeks, URGN has traded between US$15.86 and US$50.81. On Syfe you can trade URGN with $0 commission and add it to your watchlist.
| Previous close | US$44.09 |
|---|---|
| Market cap | US$2.29B |
| P/E ratio | 26.72 |
| 52-week range | US$15.86 – US$50.81 |
| Volume | 779.04K |
| Exchange | US |
Add to Watchlist
Set Price Alert
UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Year: 2017
UroGen Pharma Ltd. (URGN) stock is trading at US$44.34, +0.56% from the previous close of US$44.09.
The market cap for UroGen Pharma Ltd. (URGN) stock is approximately US$2.29B.
The price-to-earnings ratio for UroGen Pharma Ltd. (URGN) is 26.72, based on the latest reported earnings.
The 52-week high for UroGen Pharma Ltd. (URGN) stock is US$50.81.
The 52-week low for UroGen Pharma Ltd. (URGN) stock is US$15.86.
UroGen Pharma Ltd. (URGN) does not currently pay a dividend.
Stay on top of URGN
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
